» Articles » PMID: 28885988

Dapsone-induced Severe Cutaneous Adverse Drug Reactions Are Strongly Linked with HLA-B*13: 01 Allele in the Thai Population

Abstract

Objectives: A previous publication in Chinese leprosy patients showed that the HLA-B*13:01 allele is a strong genetic marker for dapsone-induced drug hypersensitivity reactions, however there are no data describing whether HLA-B*13:01 is a valid marker for prediction of dapsone-induced drug hypersensitivity reactions in other ethnicities or nonleprosy patients. The aim of this study is to investigate whether there is an association between HLA genotypes and dapsone-induced severe cutaneous adverse reactions (SCARs) in Thai nonleprosy patients.

Patients And Methods: HLA-B genotypes of 15 patients with dapsone-induced SCARs (11 drug reaction with eosinophilia and systemic symptoms, 4 Stevens-Johnson syndrome/toxic epidermal necrolysis), 29 control patients, and 986 subjects from the general Thai population were determined by the reverse PCR sequence-specific oligonucleotides probe.

Results: The HLA-B*13:01 allele was significantly associated with dapsone-induced SCARs compared with dapsone-tolerant controls (odds ratio: 54.00, 95% confidence interval: 7.96-366.16, P=0.0001) and the general population (odds ratio: 26.11, 95% confidence interval: 7.27-93.75, P=0.0001). In addition, HLA-B*13:01 associated with dapsone-induced SJS-TEN (OR: 40.50, 95% confidence interval: 2.78-591.01, P=0.0070) and DRESS (OR: 60.75, 95% confidence interval: 7.44-496.18, P=0.0001).

Conclusion: This study demonstrated an association between HLA-B*13:01 and dapsone-induced SCARs including Stevens-Johnson syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms in nonleprosy patients. Moreover, these results suggest that the HLA-B*13:01 allele may be a useful genetic marker for prediction of dapsone-induced SCARs in Thai and Han-Chinese populations.

Citing Articles

The Occurrence of Etoricoxib-Induced Stevens-Johnson Syndrome With Oral Manifestations in a Female Patient: A Case Study.

Zisis V, Papadopoulos P, Kyriakou N, Charisi C, Poulopoulos A Cureus. 2024; 16(6):e63353.

PMID: 39077250 PMC: 11283930. DOI: 10.7759/cureus.63353.


Phenomic landscape and pharmacogenomic implications for HLA region in a Taiwan Han Chinese population.

Chou W, Chen L, Wong H, Chao C, Chu H, Chang W Biomark Res. 2024; 12(1):46.

PMID: 38702819 PMC: 11067262. DOI: 10.1186/s40364-024-00591-z.


Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy.

de Araujo A, Hacker M, Pinheiro R, Illarramendi X, Duraes S, Nobre M PLoS Negl Trop Dis. 2024; 18(1):e0011901.

PMID: 38271456 PMC: 10846698. DOI: 10.1371/journal.pntd.0011901.


A Compilation of Drug Etiologies of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Abulatan I, Ben-David S, Morales-Colon L, Beason E, Fakoya A Cureus. 2023; 15(11):e48728.

PMID: 38094551 PMC: 10718167. DOI: 10.7759/cureus.48728.


HLA-targeted sequencing reveals the pathogenic role of HLA-B*15:02/HLA-B*13:01 in albendazole-induced liver failure: a case report and a review of the literature.

Liao J, Zhan Y, Zhang Z, Cui J, Yin J Front Pharmacol. 2023; 14:1288068.

PMID: 38027017 PMC: 10670799. DOI: 10.3389/fphar.2023.1288068.